Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Actuate Therapeutics, Inc. ( (ACTU) ) just unveiled an update.
On May 22, 2025, Actuate Therapeutics, Inc. held its Annual Meeting of Stockholders virtually, where stockholders elected three Class I directors to the Board for a three-year term and ratified Crowe LLP as the independent accounting firm for 2025. This event underscores the company’s commitment to maintaining strong governance and financial oversight, potentially impacting its operational stability and investor confidence.
The most recent analyst rating on (ACTU) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Actuate Therapeutics, Inc. stock, see the ACTU Stock Forecast page.
More about Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapeutics for the treatment of cancer and other diseases.
Average Trading Volume: 49,649
Technical Sentiment Signal: Strong Buy
For a thorough assessment of ACTU stock, go to TipRanks’ Stock Analysis page.